Corcept: President of Endocrinology Sean Maduck retires Oct 1; Justin Gunn succeeds

CORCEPT THERAPEUTICS INC

Sean Maduck resigns as President, Endocrinology, effective Oct 1, 2026; no disagreement cited.
Justin Gunn appointed President, Endocrinology, assumes role Oct 1; joins Executive Team, reports to CEO.
Maduck signs consulting agreement at $57k/month through Sept 30, 2027; stock options keep vesting.
Gunn joined Corcept July 2024 as VP Sales; led sales org for Lifyorli launch; 18 yrs at Gilead.
Maduck will remain as senior commercial advisor to ensure smooth transition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.